CORDIS
EU research results

CORDIS

English EN
Biomarkers of renal graft injuries in kidney allograft recipients

Biomarkers of renal graft injuries in kidney allograft recipients

Objective

In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient treatment, quality of life and long-term graft survival. Also, there is an unmet need for better understanding of the immune and non-immune mechanisms of interstitial fibrosis /tubular atrophy and graft loss.
Combining all the skills required to build upon previous findings, BIOMARGIN will offer such opportunities in renal transplantation by integrating several omics approaches (mRNA, miRNA, peptides, proteins, lipids and metabolites) in blood, graft tissue and urine, in a well thought out, multistage discovery-to-validation translational programme, following the highest European ethics and regulatory requirements, as well as quality controls and quality assessments at all clinical and analytical steps. It is probably one of the first programmes to pursue such an integrated and systematic research approach.
BIOMARGIN aims to: (i) discover, select and validate blood and/or urine biomarkers of renal allograft lesions in adult and pediatric kidney transplant recipients; (ii) provide renal transplant physicians with non-invasive, robust diagnostic tests and interpretation algorithms enabling closer, more accurate, more predictive and/or less invasive monitoring of transplanted patients; (iii) help to avoid or diminish the use of biopsies and improve patient treatment, quality of life and long-term graft survival; (iv) help understand the mechanisms involved in the allograft injury processes which, combined with mass spectrometry imaging should offer pathologists new molecular targets and tools for renal graft biopsy analysis.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 509 502

Administrative Contact

Muriel Bouas (Ms.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

INSERM TRANSFERT SA

France

EU Contribution

€ 455 400

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 305 820

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 455 576

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 201 358

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 748 000

VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V.

Belgium

EU Contribution

€ 273 016

MOSAIQUES DIAGNOSTICS GMBH

Germany

EU Contribution

€ 256 259

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 306 407

Cardinal Systems

France

EU Contribution

€ 627 462

UNIVERSITE PARIS DESCARTES

France

EU Contribution

€ 309 000

AcureOmics AB

Sweden

EU Contribution

€ 311 000

Centre hospitalier universitaire de Limoges

France

EU Contribution

€ 241 200

Project information

Grant agreement ID: 305499

Status

Closed project

  • Start date

    1 March 2013

  • End date

    28 February 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 836 208

  • EU contribution

    € 6 000 000

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France